Forest Laboratories Inc. on Tuesday stated a quarterly profit, bolstered with higher sales of its flagship drugs for depression and Alzheimer's disease.
The drugmaker reported a fiscal fourth-quarter profit of $172.8 million, or 55 cents per share. That compared with a net loss of $237.9 million, or 75 cents per share, a year ago, when Forest took a big charge for an acquisition.
Results included a 35-cent per-share charge for a licensing payment.
Forest Laboratories is a pharmaceutical company headquartered in New York City, USA. Its revenues for the year ended 31 March 2007 were US$3.4 billion. The company's research & development spending has grown rapidly in recent years, and as of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.
Most EU countries are allied with US-dominated NATO - a killing machine involved in smashing one sovereign state after another. It's responsible for vast destruction, millions of casualties, and appalling human misery from the rape of Yugoslavia and post-9/11 US-led wars of aggression - based on Big Lies and deception.